A Multicenter Retrospective Cohort Study of Practice Patterns and Clinical Outcomes of the Use of Darbepoetin Alfa and Epoetin Alfa for Chemotherapy-Induced Anemia

Clinical Therapeutics

Volumn 25, Issue 11, 2003, Pages 2781-2796

  Schwartzberg, Lee ^a,e   Shiftman, Roger ^b   Tomita, Dianne ^c   Stolshek, Bradley ^c   Rossi, Greg ^c   Adamson, Robert ^d  

^a Supportive Oncology Services Incorporated   (United States)

^b Monterey Bay Oncol and Genet Ctr   (United States)

^c AMGEN INC   (United States)

^d Saint Barnabas Healthcare System   (United States)

^e WEST CLINIC   (United States)

Author keywords

Anemia; Darbepoetin alfa; Erythropoiesis; Hemoglobin

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTIMETABOLITE; ANTINEOPLASTIC AGENT; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLATINUM DERIVATIVE; RECOMBINANT ERYTHROPOIETIN; TAXANE DERIVATIVE;

ADULT; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED ANEMIA; COHORT ANALYSIS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG UTILIZATION; ERYTHROCYTE TRANSFUSION; FEMALE; HEMOGLOBIN DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; MULTICENTER STUDY; ONCOLOGY; UNITED STATES;

EID: 0344664553     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(03)80333-8     Document Type: Article

References (27)

1. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: Incidence and treatment. J Natl Cancer Inst. 1999;91:1616-1634.
2. Curt GA. Impact of fatigue on quality of life in oncology patients. Semin Hematol. 2000;37(Suppl 6):14-17.
3. Curt GA, Breitbart W, Cella D, et al. Impact of cancer-related fatigue on the lives of patients: New findings from the Fatigue Coalition. Oncologist. 2000;5:353-360.
4. Vogelzang NJ, Breitbart W, Cella D, et al, for the Fatigue Coalition. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: Results of a tripart assessment survey. Semin Hematol. 1997;34(Suppl 2):4-12.
5. Platanias LC, Miller CB, Mick R, et al. Treatment of chemotherapy- induced anemia with recombinant human erythropoietin in cancer patients. J Clin Oncol. 1991;9:2021-2026.
6. Cascinu S, Fedeli A, Del Ferro E, et al. Recombinant human erythropoietin treatment in cisplatin-associated anemia: A randomized, double-blind trial with placebo. J Clin Oncol. 1994;12:1058-1062.
7. Oberhoff C, Neri B, Amadori D, et al. Recombinant human erythropoietin in the treatment of chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: A randomized, controlled study. Ann Oncol. 1998;9:255-260.
8. Cazzola M, Messinger D, Battistel V, et al. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: Dose finding and identification of predictors of response. Blood. 1995;86:4446-4453.
9. Österborg A, Boogaerts MA, Cimino R, et al, for the European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and Non-Hodgkins Lymphoma. Recombinant human erythropoietin in transfusion- dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma - a randomized multicenter study. Blood. 1996;87:2675-2682.
10. Elliott S, Lorenzini T, Asher S, et al. Enhancement of therapeutic protein in vivo activities through glycoengineering. Nat Biotechnol. 2003;21:414-421.
11. Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer. 2001;84(Suppl 1):3-10.
12. Macdougall IC, Gray S, Elston O, et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol. 1999; 10:2392-2395.
13. Glaspy JA, Tchekmedyian NS. Darbepoetin alfa administered every 2 weeks alleviates anemia in cancer patients receiving chemotherapy. Oncology (Huntingt). 2002;16(Suppl 11):23-29.
14. Mirtsching B, Charu V, Vadhan-Raj S, et al. Every-2-week darbepoetin alfa is comparable to rHuEPO in treating chemotherapy-induced anemia. Results of a combined analysis. Oncol (Huntingt). 2002;16(Suppl 11):31-36.
15. Kotasek D, Steger G, Faught W, et al. Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy: Results of a double-blind, placebo-controlled, randomised study. Eur J Cancer. 2003;39:2026-2034.
16. Kotasek D, Albertsson M, Mackey J, et al. Once per cycle dosing of darbepoetin alfa is feasible in anemic cancer patients receiving chemotherapy. Ann Oncol. 2002; 13(Suppl 5):170. Abstract.
17. Phillips MS, Gayman JE, Todd MW, for the American Society of Health-System Pharmacists. ASHP guidelines on medication-use evaluation. Am J Health Syst Pharm. 1996; 53:1953-1955.
18. Rittenhouse BE, O'Brien BJ. Threats to the validity of pharmacoeconomics analyses based on clinical trial data. In: Spilker B, ed. Quality of Life and Pharmacoeconomics in Clinical Trials. 2nd ed. Philadelphia: Lippincott-Raven; 1996:1215-1223.
19. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med. 2000;342:1887-1892.
20. Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med. 2000;342:1878-1886.
21. Croghan TW, Johnstone BM, Buesching DP, Kessler RC. Information needs for medication coverage decisions in a state Medicaid program. Med Care. 1999;37(Suppl 4):AS24-AS31.
22. Motheral B, Brooks J, Clark MA, et al. A checklist for retrospective database studies - report of the ISPOR task force on retrospective databases. Value Health. 2003;6:90-97.
23. West S, King V, Carey TS, et al. Evidence Report/Technology Assessment No. 47: Systems to Rate the Strength of Scientific Evidence. Rockville, Md: Agency for Healthcare Research and Quality; April 2002. AHRQ Publication 02-E016.
24. Workshop on drug utilization review. Rockville, Maryland, November 26-27, 1990. Proceedings. Clin Pharmacol Ther. 1991;50:593-640.
25. Food and Drug Administration. Guidance for Industry. E9 Statistical Principles for Clinical Trials. September 1998. Available at: http://www.fda.gov/cder/guidance/ICH_E9-fnl. pdf. Accessed August 10, 2003.
26. Demetri GD, Kris M, Wade J, et al, for the Procrit Study Group. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study. J Clin Oncol. 1998;16:3412-3425.
27. Gabrilove JL, Cleeland CS, Livingston RB, et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol. 2001;19:2875-2882.